Literature DB >> 2117017

Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat.

J Reith1, S Dyve, H Kuwabara, M Guttman, M Diksic, A Gjedde.   

Abstract

In a study designed to reveal the rates of blood-brain transfer and decarboxylation of fluoro-L-3,4-dihydroxyphenylalanine (FDOPA), we discovered a major discrepancy between the DOPA decarboxylase activity reported in the literature and the rate of FDOPA decarboxylation measured in the study. "Donor" rats received intravenous injections of 6 mCi fluorine-18-labeled FDOPA. The donor rats synthesized methyl-FDOPA. Arterial plasma, containing both FDOPA and methyl-FDOPA, was sampled from the donor rats at different times and reinjected into "recipient" rats in which it circulated for 20 s. The blood-brain clearance of the mixture of labeled tracers in the plasma was determined by an integral method. The individual permeabilities were determined by linear regression analysis, according to which the average methyl-FDOPA permeability in the blood-brain barrier was twice that of FDOPA, which averaged 0.037 ml g-1 min-1. The permeability ratio was used to determine the fractional clearance from the brain of FDOPA (and hence of methyl-FDOPA), which averaged 0.081 min-1. In the striatum, the measured average FDOPA decarboxylation rate constant (kD3) was 0.010 min-1, or no more than 1% of the rate of striatal decarboxylation of DOPA measured in vitro and in vivo. We interpreted this finding as further evidence in favor of the hypothesis that striatum has two dopamine (DA) pools, of which only DA in the large pool is protected from metabolism. Hence, no more than 1% of the quantity of fluoro-DA theoretically synthesized was actually retained in striatum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117017     DOI: 10.1038/jcbfm.1990.124

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  6 in total

1.  Dopa decarboxylase activity of the living human brain.

Authors:  A Gjedde; J Reith; S Dyve; G Léger; M Guttman; M Diksic; A Evans; H Kuwabara
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  Elevated dopa decarboxylase activity in living brain of patients with psychosis.

Authors:  J Reith; C Benkelfat; A Sherwin; Y Yasuhara; H Kuwabara; F Andermann; S Bachneff; P Cumming; M Diksic; S E Dyve; P Etienne; A C Evans; S Lal; M Shevell; G Savard; D F Wong; G Chouinard; A Gjedde
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

3.  Positron emission tomographic measure of brain dopamine dependence to nicotine as a model of drugs of abuse.

Authors:  Edward F Domino; Hideo Tsukada; Norihiro Harada
Journal:  Psychopharmacology (Berl)       Date:  2009-01-10       Impact factor: 4.530

4.  In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Siobhan McCormick; Chenoa Mah; James E Holden; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

5.  Quantification of [(11)C]yohimbine binding to α2 adrenoceptors in rat brain in vivo.

Authors:  Jenny-Ann Phan; Anne M Landau; Dean F Wong; Steen Jakobsen; Adjmal Nahimi; Doris J Doudet; Albert Gjedde
Journal:  J Cereb Blood Flow Metab       Date:  2015-01-07       Impact factor: 6.200

6.  Radioligand binding analysis of α 2 adrenoceptors with [11C]yohimbine in brain in vivo: Extended Inhibition Plot correction for plasma protein binding.

Authors:  Jenny-Ann Phan; Anne M Landau; Steen Jakobsen; Dean F Wong; Albert Gjedde
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.